Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

This study is testing a three-drug combination — fruquintinib, S-1, and raltitrexed — for people with metastatic colorectal cancer that has stopped responding to standard chemotherapy. All three drugs target cancer cell growth through different pathways. **You may be eligible if...** - You are 18 or older - You have metastatic colorectal cancer confirmed by biopsy - Your cancer has progressed after standard treatments including 5-FU, irinotecan, and oxaliplatin (and targeted drugs if applicable) - You have measurable tumors on scans - You are in good overall health (ECOG 0–2) - You have a life expectancy of at least 12 weeks - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have had a recent chemotherapy session without adequate recovery time - Your blood counts or organ function fall below study thresholds - You are pregnant or breastfeeding - You have an active serious infection Talk to your doctor to see if this trial is right for you.